Alpha 2.0
Login Register
» Authors » Roman Wieczorek

Roman Wieczorek

Explore the profile of Roman Wieczorek including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 127
Followers 0
Related Specialties
Biology
Toxicology
Pharmacology
Top 10 Co-Authors
Liam Simms
Matthew Stevenson
Edgar Trelles Sticken
Fiona Chapman
Lukasz Czekala
Kathryn Rudd
Sarah Jean Pour
Fan Yu
Jessica Budde
Tanvir Walele
Published In
Front Toxicol
Curr Res Toxicol
Altern Lab Anim
Microbiology (Reading)
Toxicol In Vitro
Affiliations
Soon will be listed here.
Recent Articles
1.
Optimisation of an human cardiovascular model on-a-chip for toxicological assessment of nicotine delivery products
Chapman F, de Haan L, Gijzen L, Strijker W, Sticken E, Pour S, et al.
Front Toxicol . 2024 Jun; 6:1395670. PMID: 38938662
Background: Smoking cigarettes is a cause of serious diseases in smokers, including cardiovascular disease. Through a pathway of endothelial dysfunction, lipid infiltration, macrophage recruitment and vascular remodeling, atherosclerosis is fundamental...
2.
Use of quantitative to extrapolation (QIVIVE) for the assessment of non-combustible next-generation product aerosols
Moreau M, Simms L, Andersen M, Sticken E, Wieczorek R, Pour S, et al.
Front Toxicol . 2024 Apr; 6:1373325. PMID: 38665213
With the use of new approach methodologies (NAMs) for the assessment of non-combustible next-generation nicotine delivery products, new extrapolation methods will also be required to interpret and contextualize the physiological...
3.
Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke
Chapman F, Pour S, Wieczorek R, Sticken E, Budde J, Rower K, et al.
Front Toxicol . 2023 Mar; 5:1076752. PMID: 36875887
Tobacco harm reduction (THR) involves providing adult smokers with potentially reduced harm modes of nicotine delivery as alternatives to smoking combustible cigarettes. Heated tobacco products (HTPs) form a category with...
4.
Key Challenges and Recommendations for Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters
Moore M, Abraham I, Ballantyne M, Behrsing H, Cao X, Clements J, et al.
Altern Lab Anim . 2023 Feb; 51(1):55-79. PMID: 36821083
The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific and technical approaches for conducting assays, to assess...
5.
Characterisation of a smoke/ aerosol exposure in vitro system (SAEIVS) for delivery of complex mixtures directly to cells at the air-liquid interface
Wieczorek R, Sticken E, Pour S, Chapman F, Rower K, Otte S, et al.
J Appl Toxicol . 2023 Feb; 43(7):1050-1063. PMID: 36734622
In vitro testing is important to characterise biological effects of consumer products, including nicotine delivery products such as cigarettes, e-cigarettes and heated tobacco products. Users' cells are exposed to these...
6.
Multiple endpoint in vitro toxicity assessment of a prototype heated tobacco product indicates substantially reduced effects compared to those of combustible cigarette
Chapman F, Sticken E, Wieczorek R, Pour S, Dethloff O, Budde J, et al.
Toxicol In Vitro . 2022 Nov; 86:105510. PMID: 36372310
This study aimed to compare the aerosol chemistry and in vitro toxicological profiles of two prototype Heated Tobacco Product (p-HTP) variants to the 1R6F Reference Cigarette. In the neutral red...
7.
Ciliary Beat Frequency: Proceedings and Recommendations from a Multi-laboratory Ring Trial Using 3-D Reconstituted Human Airway Epithelium to Model Mucociliary Clearance
Behrsing H, Wahab A, Ukishima L, Grodi C, Frentzel S, Johne S, et al.
Altern Lab Anim . 2022 Aug; 50(4):293-309. PMID: 35938181
The use of reconstituted human airway (RHuA) epithelial tissues to assess functional endpoints is highly relevant in respiratory toxicology, but standardised methods are lacking. In June 2015, the Institute for...
8.
Key challenges for in vitro testing of tobacco products for regulatory applications: Recommendations for dosimetry
Miller-Holt J, Behrsing H, Crooks I, Curren R, Demir K, Gafner J, et al.
Drug Test Anal . 2022 Jul; 15(10):1175-1188. PMID: 35830202
The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to develop recommendations for optimal scientific and technical approaches for conducting in vitro assays to assess potential...
9.
Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products
Simms L, Yu F, Palmer J, Rudd K, Sticken E, Wieczorek R, et al.
Front Toxicol . 2022 Mar; 4:747508. PMID: 35295225
Combustible cigarette smoking is an established risk factor for cardiovascular disease. By contrast, the cardiotoxicity potential of non-combustible next generation nicotine products (NGPs), which includes heated tobacco products (HTPs) and...
10.
Use of a rapid human primary cell-based disease screening model, to compare next generation products to combustible cigarettes
Simms L, Mason E, Berg E, Yu F, Rudd K, Czekala L, et al.
Curr Res Toxicol . 2021 Sep; 2:309-321. PMID: 34485931
A growing number of public health bodies, regulators and governments around the world consider electronic vapor products a lower risk alternative to conventional cigarettes. Of critical importance are rapid new...